estimates of attributable risk factors for lung cancer in Nanjing, China. Lung cancer
| bsp; Xinghe Wang, Jiadong Zhou, Yuda Zong K. Craig Goodrich, Lei Yu,
25. Zheng-Rong Lu Antitumor Efficacy of Anti-VEGF SiRNA Complexes with a Degradable Cationic Polymer (abstract) 2004.6. 10-15. CRS meeting 26. Zheng-Rong Lu, Dennis L. Parker, K.Craig Goodrich, Xinghe Wang, John G. Dalle and Henry R. Buswell. Extracellular Biodegradable Macromolecular Gadolinium(III) Complexes for MRI. Magnetic Resonance in Medicine 2004, 51: 27-34 22. Zheng-Rong Lu, Xinghe Wang Poly(L-Glutamic Acid) Gd(III)-DOTA conjugate with controlled degradation for magnetic resonance imagine. Bioconjugate Chem. 2003,14(4) 715-719 21. Xinghe Wang and Zheng-Rong Lu, Degradablility and Pharmacokinetics of the Macromolecular Gadolinium(III)-DTPA-Cystamine Copolymeres. AAPS Meeting 2003,10, 26-30 20. Xinghe Wang and Zheng-Rong Lu, In vivo degradation of Gd-DTPA * systamine copolymers. Submitted, Imaging. 2004 19. Xinghe wang. Aptamers with Anti-VEGF target treatment breast cancer. Submitted, Cancer Research (2004) 18. Shaobo Zhang, Xinghe Wang, Liang Cheng. Androgen Up-regulated VEGF in CWR22 Human Prostate Cancer Model. Cancer. Submitted (2004) 17. Xinghe Wang, Qin Mei, Fan Shaozeng.Study on gene expression of MAP-II, NSE, S-100,GFAP in neocortex striatum, hippocampus thalamus of SD rats. Chin J.Contem. Pediatr 2000, 2(6):381 16. Xinghe Wang, Qin Mei, Fan Shaozeng. NSE, S-100,GFAP,MBP,CK-BB in the blood and the C.S.F after hypoxic- ischemic brain damage in newborn rats and asphyxiated full-term infants. Chin. J. Peditr. 1999, 11, 178 15. Xinghe Wang, Yang Yi, Fan Shaozeng.Study on the express of mRNA for NSE, GFAP and S-100 protein in hypoxic- ischemic brain injury. Chin. J. Perinatology.1999, 2, 89 14. Qin Mei, Xinghe Wang, Fan Shaozeng. Establishment of a model of hypothermia intervention after hypoxic-ischemic brain damage in newborn rats. Shanghai Experimental Animal Science 1999, 19(2):76-81 13. Qin Mei, Xinghe Wang, Fan Shaozeng. Experimental study on protective effects of hypothermia and/or magnesium sulphate on hypoxic-ischemic brain damage. Shanghai Med J. 1999, 4 , 210-213 12. Qin Mei, Xinghe Wang, Fan Shaozeng. Protective effects of hypothermia in hypoxic-ischemic brain injury in newborn rats. Chin J Perinatology. 1998, 8:105-108 11. Xinghe Wang Fan Shaozeng. Development of Diagnosis and treatment
of asphyxiated full-term infants. Chin. J. Pediatr. 1997, 3, 162-164 10. Xiaobing Shen, Xinghe Wang. Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung cancer.1996 14 (suppl.1) S107-S112 9. Zhi Wenjing, Xinghe Wang, Wu Wenshui. A seroepidemiological investigation on childamydia pneumoniae strain TWAR in infectation in children in Beijing. Chin. J. Pediatr. 1996, 5: 1-3 8. Zhi Wenjing, Xinghe Wang, Guo Jian Feng. Study on infection of chlamychia pneumonial strain (TWAR) in child. Chin. J. Epidemiology.1996, 2A: 7. Chief editor two books (1). Xinghe Wang, Zhang Hua. Prevention and strategy of common diseases for parents. XUE YAN publishing house. 1996, 8. Beijing, China. ISBN 7-80020-667- X/R. 599 (2). Xinghe Wang. Diagnosis and treatment of common diseases in child.REN MIN Army Medical publishing house.1994,10. Beijing, China. ISBN 7-5077-0956-6/R.155 6. Xinghe Wang, Linmin Wu. Study on protective mechanism of FDP on hypoxic-ischemic brain damage. Foreign Medical Sciences (Pediatrics). 1995, 22(sup), 49-51. Review 5. Xinghe Wang. Pathogenesis of coronary lesion in Kawasaki disease. China Medical Abstracts (Internal medicine)1994, 6 sup 259 4. Xinghe Wang. Clinical study antibiotic adverse reactions. China Medical Abstracts 1995, 10 sup 168 3. Xinghe Wang Myplasm pneumia clinical analysis. China Medical Abstracts (Internal medicine ) 1994, 6 sup 389 2. Xinghe Wang. Clinical research multi-antibiotic for treatment on infection of diseases. China Medical Abstracts (Internal medicine) 1994,11 sup 366. 1. Xinghe Wang. Myplasm pneumia clinical research. National Medical J. China.1991, 8:16 项目报告: 1.集中发展新药和基因治疗的运载系统,发展和设计新的药物控释和靶向性的运载工具 2.新药设计和发展生物可降解的研究 3.药物靶向性设计和发展新药的研究 4.基因治疗的非病毒运载工具的研究 5.生物可降解大分子核磁共震造影剂的开发 6.熟练掌握临床病例分组及用药设计. 7.临床试验1,2,3,4期试验 |
See all the reviews